Lepu Medical Technology (Beijing) Co., Ltd.
300003
Rang in Aktien
#4732
Established in 1999 and headquartered in Beijing, China, Lepu Medical... Established in 1999 and headquartered in Beijing, China, Lepu Medical Technology is a prominent company dedicated to the research, development, production, and sale of a broad spectrum of medical devices, pharmaceuticals, and healthcare services. The company's extensive medical device portfolio primarily focuses on cardiovascular health. This includes interventional cardiology products such as coronary stents, balloons, catheters, guide wires, and related PCI accessories. It also provides solutions for structural heart diseases, like occluders, vascular plugs, delivery systems, and mechanical heart valves. Lepu Medical offers cardiac rhythm management products, including pacemakers, equipment, leads, and electrophysiology systems, alongside products for off-pump coronary artery bypass grafting and peripheral interventional devices such as PTA balloons and guide wires. Beyond cardiovascular applications, their offerings extend to critical care products like vascular access devices, needle-free connectors, blood samplers, and pressure transducers. The company also provides digital subtraction angiography (DSA) systems (both floor and suspended types), in vitro diagnostic (IVD) equipment and biomarkers, hemodialysis catheters and hollow fiber dialyzers, and general surgery instruments including surgical staplers and endo surgery accessories. In the pharmaceutical sector, Lepu Medical manufactures and distributes medications for various conditions. This encompasses a comprehensive range of cardiovascular drugs designed to treat issues like thrombosis, hyperlipidemia, hypertension, angina, and heart failure. Additionally, they produce beta-lactamase antibiotics and antifungal antimicrobial drugs, central nervous system medications (such as painkillers and antidepressants), treatments for gastric/duodenal ulcers and chronic liver disease, respiratory system drugs, hypoproteinemia drugs, and agents that activate blood circulation. Furthermore, Lepu Medical provides a diverse array of healthcare services. These include precision medicine, remote ECG telemonitoring, and specialized consulting and management centers for cardiovascular diseases. The company is also involved in medical science and technology incubation, equity investment, and offers medical financial services. Its service offerings extend to general health consultation, online pharmacy platforms, sales of household medical equipment, smart medical devices, and the operation of specialized hospitals focusing on cardiovascular care. Lepu Medical actively participates in the establishment and co-construction of cardiac catheterization laboratories (Cath Labs).
Aktienkurs
$1.73
Marktkapitalisierung
$3.18B
Veränderung (1 Tag)
2.76%
Veränderung (1 Jahr)
-32.27%
Land
CN
Handel Lepu Medical Technology (Beijing) Co., Ltd. (300003)
Kategorie
Healthcare
KGV für Lepu Medical Technology (Beijing) Co., Ltd. (300003)
KGV zum October 2026 TTM: 26.94
Laut den neuesten Finanzberichten und dem Aktienkurs von Lepu Medical Technology (Beijing) Co., Ltd. beträgt das aktuelle P/E-Verhältnis (TTM) 26.94. Am Ende des Jahres 2023 hatte das Unternehmen ein P/E von 23.68.
P/E-Verlaufsdaten für Lepu Medical Technology (Beijing) Co., Ltd. von 2006 bis 2026
P/E-Verhältnis am Ende jedes Jahres
| Jahr | KGV | ändert |
|---|---|---|
| 2026 (TTM) | 26.94 | -68.26% |
| 2024 | 84.88 | 258.42% |
| 2023 | 23.68 | 26.07% |
| 2022 | 18.78 | -20.35% |
| 2021 | 23.58 | -12.01% |
| 2020 | 26.80 | -21.04% |
| 2019 | 33.94 | 15.62% |
| 2018 | 29.36 | -36.13% |
| 2017 | 45.97 | 0.31% |
| 2016 | 45.82 | -23.84% |
| 2015 | 60.16 | 31.75% |
| 2014 | 45.66 | 21.35% |
| 2013 | 37.63 | 104.00% |
| 2012 | 18.45 | -21.43% |
| 2011 | 23.48 | -56.69% |
| 2010 | 54.20 | -17.55% |
| 2009 | 65.74 | -42.79% |
| 2008 | 114.92 | -10.24% |
| 2007 | 128.03 | 5.55% |
| 2006 | 121.29 | 0.00% |
P/E-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/E Ratio | P/E Ratio-Differenz | Land |
|---|---|---|---|
| 33.11 | 22.91% |
US
|
|
| 21.39 | -20.61% |
IE
|
|
| 28.94 | 7.45% |
US
|
|
| 17.34 | -35.64% |
US
|
|
| - | - |
DE
|
Wie liest man ein P/E Ratio?
Das Kurs-Gewinn-Verhältnis (P/E Ratio) misst das Verhältnis zwischen dem Aktienkurs eines Unternehmens und seinem Gewinn pro Aktie.
Ein niedriges, aber positives P/E weist auf ein Unternehmen hin, das hohe Gewinne im Verhältnis zur aktuellen Bewertung erzielt und möglicherweise unterbewertet ist. Ein Unternehmen mit einem hohen negativen (nahe 0) P/E macht hohe Verluste im Verhältnis zur Bewertung.
Unternehmen mit einem P/E über 30 oder negativ werden allgemein als "Wachstumsaktien" betrachtet, was bedeutet, dass Investoren erwarten, dass das Unternehmen in Zukunft wächst oder profitabel wird.
Unternehmen mit einem positiven P/E unter 10 gelten im Allgemeinen als "Value-Aktien", was bedeutet, dass das Unternehmen bereits sehr profitabel ist, aber in Zukunft wahrscheinlich kein starkes Wachstum aufweisen wird.